The enhancement of bone allograft incorporation by the local delivery of the sphingosine 1-phosphate receptor targeted drug FTY720

Biomaterials

Volumn 31, Issue 25, 2010, Pages 6417-6424

  Petrie Aronin, Caren E ^a   Shin, Soo J ^a   Naden, Kimberly B ^a   Rios, Peter D ^a   Sefcik, Lauren S ^a,b   Zawodny, Sarah R ^c   Bagayoko, Namory D ^c   Cui, Quanjun ^c   Khan, Yusuf ^d   Botchwey, Edward A ^a,c  

^a University of Virginia   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Angiogenesis; Bone tissue engineering; Drug delivery; Osseointegration

Indexed keywords

ANGIOGENESIS; BONE ALLOGRAFTS; BONE TISSUE ENGINEERING; DELIVERY SYSTEMS; IN-VITRO; LOADING EFFICIENCY; LOCAL DELIVERY; LOCALIZED DELIVERY; MECHANICAL EVALUATION; MECHANICAL INSTABILITIES; OSSEOINTEGRATION; OSSEOUS INTEGRATION; PHARMACOLOGICAL AGENTS; POLYMER COATING SYSTEMS; POROUS STRUCTURES; SMALL MOLECULES; SMOOTH MUSCLE CELLS; SPHINGOSINE 1 PHOSPHATES; TREATMENT GROUP; VASCULAR REMODELING; VASCULARIZATION;

BIOLOGICAL MATERIALS; BIOMATERIALS; BONE; COATINGS; DRUG DELIVERY; MECHANICAL PROPERTIES; MECHANICAL STABILITY;

TISSUE ENGINEERING;

COLLAGEN FIBRIL; FINGOLIMOD; POLYGLACTIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; BIOMATERIAL; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE ALLOGRAFT; BONE DEFECT; BONE DENSITY; BONE REGENERATION; BONE REMODELING; COMPRESSIVE STRENGTH; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HEALING; HOST; IN VITRO STUDY; LEUKOCYTE MIGRATION INHIBITION; MALE; MATERIAL COATING; NONHUMAN; POROSITY; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; TIBIA; YOUNG MODULUS; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; ANGIOGENESIS; ANIMAL; BONE; BONE TRANSPLANTATION; CHEMISTRY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TISSUE ENGINEERING; ULTRASTRUCTURE;

ANIMALS; BONE AND BONES; BONE REMODELING; BONE TRANSPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; COMPRESSIVE STRENGTH; ELASTIC MODULUS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; OSSEOINTEGRATION; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; TISSUE ENGINEERING; TRANSPLANTATION, HOMOLOGOUS;

EID: 77953963056     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.04.061     Document Type: Article

References (36)

1. Giannoudis P.V., Dinopoulos H., Tsiridis E. Bone substitutes: an update. Injury 2005, 36(Suppl. 3):S20-S27.
2. Greenwald A.S., Boden S.D., Goldberg V.M., Khan Y., Laurencin C.T., Rosier R.N. Bone-graft substitutes: facts, fictions, and applications. J Bone Joint Surg Am 2001, 83-A(Suppl. 2):98-103. American Academy of Orthopaedic Surgeons. The Committee on Biological Implants, Pt 2.
3. Wheeler D.L., Enneking W.F. Allograft bone decreases in strength in vivo over time. Clin Orthop Relat Res 2005, 435:36-42.
4. Delloye C., de Nayer P., Allington N., Munting E., Coutelier L., Vincent A. Massive bone allografts in large skeletal defects after tumor surgery: a clinical and microradiographic evaluation. Arch Orthop Trauma Surg 1988, 107:31-41.
5. Mankin H.J., Hornicek F.J., Raskin K.A. Infection in massive bone allografts. Clin Orthop Relat Res 2005, 432:210-216.
6. Vander Griend R.A. The effect of internal fixation on the healing of large allografts. J Bone Joint Surg Am 1994, 76:657-663.
7. Boraiah S., Paul O., Hawkes D., Wickham M., Lorich D.G. Complications of recombinant human BMP-2 for treating complex tibial plateau fractures: a preliminary report. Clin Orthop Relat Res 2009, 467:3257-3262.
8. Delloye C., Cornu O., Druez V., Barbier O. Bone allografts: what they can offer and what they cannot. J Bone Joint Surg Br 2007, 89:574-579.
9. Thompson R.C., Pickvance E.A., Garry D. Fractures in large-segment allografts. J Bone Joint Surg Am 1993, 75:1663-1673.
10. Zhang H., Desai N.N., Olivera A., Seki T., Brooker G., Spiegel S. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol 1991, 114:155-167.
11. Cuvillier O., Pirianov G., Kleuser B., Vanek P.G., Coso O.A., Gutkind S., et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996, 381:800-803.
12. Lee M.J., Thangada S., Paik J.H., Sapkota G.P., Ancellin N., Chae S.S., et al. Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol Cell 2001, 8:693-704.
13. Ryu J., Kim H.J., Chang E.J., Huang H., Banno Y., Kim H.H. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J 2006, 25:5840-5851.
14. Pebay A., Bonder C.S., Pitson S.M. Stem cell regulation by lysophospholipids. Prostaglandins Other Lipid Mediat 2007, 84:83-97.
15. Ishii M., Egen J.G., Klauschen F., Meier-Schellersheim M., Saeki Y., Vacher J., et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009, 458:524-528.
16. Walter D.H., Rochwalsky U., Reinhold J., Seeger F., Aicher A., Urbich C., et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler Thromb Vasc Biol 2007, 27:275-282.
17. Wamhoff B.R., Lynch K.R., Macdonald T.L., Owens G.K. Sphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 2008, 28:1454-1461.
18. Sefcik L.S., Petrie Aronin C.E., Wieghaus K.A., Botchwey E.A. Sustained release of sphingosine 1-phosphate for therapeutic arteriogenesis and bone tissue engineering. Biomaterials 2008, 29:2869-2877.
19. Petrie Aronin C., Sefcik L.S., Tholpady A., Sadik K.W., Tholpady S.S., Macdonald T.L., et al. FTY720 promotes local microvascular network formation and regeneration of cranial bone defects. Tissue Eng Part A 2010 Mar 8, [Epub ahead of print].
20. Ramchandani M., Pankaskie M., Robinson D. The influence of manufacturing procedure on the degradation of poly(lactide-co-glycolide) 85:15 and 50:50 implants. J Control Release 1997, 43:161-173.
21. Lucarelli E., Fini M., Beccheroni A., Giavaresi G., Di Bella C., Aldini N.N., et al. Stromal stem cells and platelet-rich plasma improve bone allograft integration. Clin Orthop Relat Res 2005, 435:62-68.
22. Han B., Woodell-May J., Ponticiello M., Yang Z., Nimni M. The effect of thrombin activation of platelet-rich plasma on demineralized bone matrix osteoinductivity. J Bone Joint Surg Am 2009, 91:1459-1470.
23. Nevins M., Hanratty J., Lynch S.E. Clinical results using recombinant human platelet-derived growth factor and mineralized freeze-dried bone allograft in periodontal defects. Int J Periodontics Restorative Dent 2007, 27:421-427.
24. Yazici C., Yanoso L., Xie C., Reynolds D.G., Samulski R.J., Samulski J., et al. The effect of surface demineralization of cortical bone allograft on the properties of recombinant adeno-associated virus coatings. Biomaterials 2008, 29:3882-3887.
25. Cahill K.S., Chi J.H., Day A., Claus E.B. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. J Am Med Assoc 2009, 302:58-66.
26. Shields L.B., Raque G.H., Glassman S.D., Campbell M., Vitaz T., Harpring J., et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 2006, 31:542-547.
27. Lamberg A., Schmidmaier G., Soballe K., Elmengaard B. Locally delivered TGF-beta1 and IGF-1 enhance the fixation of titanium implants: a study in dogs. Acta Orthop 2006, 77:799-805.
28. Lewandrowski K.U., Bondre S., Hile D.D., Thompson B.M., Wise D.L., Tomford W.W., et al. Porous poly(propylene fumarate) foam coating of orthotopic cortical bone grafts for improved osteoconduction. Tissue Eng 2002, 8:1017-1027.
29. Bondre S., Lewandrowski K.U., Hasirci V., Cattaneo M.V., Gresser J.D., Wise D.L., et al. Biodegradable foam coating of cortical allografts. Tissue Eng 2000, 6:217-227.
30. Streeten E.A., Brandi M.L. Biology of bone endothelial cells. Bone Miner 1990, 10:85-94.
31. Drushel R.F., Pechak D.G., Caplan A.I. The anatomy, ultrastructure and fluid dynamics of the developing vasculature of the embryonic chick wing bud. Cell Differ 1985, 16:13-28.
32. Liu Y., Wada R., Yamashita T., Mi Y., Deng C.X., Hobson J.P., et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000, 106:951-961.
33. Paik J.H., Skoura A., Chae S.S., Cowan A.E., Han D.K., Proia R.L., et al. Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev 2004, 18:2392-2403.
34. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
35. Whetzel A.M., Bolick D.T., Srinivasan S., Macdonald T.L., Morris M.A., Ley K., et al. Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ Res 2006, 99:731-739.
36. Kimura T., Boehmler A.M., Seitz G., Kuci S., Wiesner T., Brinkmann V., et al. The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells. Blood 2004, 103:4478-4486.